We found a significant association between respiratory infections, especially influenza, and acute myocardial infarction. (Funded by the Canadian Institutes of Health Research and others.).

Abstract We enrolled 91 consecutive inpatients with COVID-19 at 6 hospitals in Toronto, Canada, and tested 1 nasopharyngeal swab/saliva sample pair from each patient using real-time RT-PCR for severe acute respiratory syndrome coronavirus 2. Sensitivity was 89% for nasopharyngeal swabs and 72% for saliva (P = .02). Difference in sensitivity was greatest for sample pairs collected later in illness.

NCT01517191.

METHODOLOGY 3.0 DEFINITIONS 3.1 General definitions 3.2 Operational definition of CA-MRSA 3.3 Definition limitations 4.0 EPIDEMIOLOGY 4.1 The rise of CA-MRSA 4.2 CA-MRSA in Canada 4.3 Origin of CA-MRSA and its ability to disseminate 4.4 Populations at risk 4.5 Transmission 5.0 MICROBIOLOGY 5.1 S aureus and MRSA 5.2 Virulence factors 5.3 Nomenclature of strains 5.4 Resistance to non-beta-lactam antibiotics 5.4.1 Clindamycin 5.4.2 Erythromycin 5.4.3 Quinolones 5.5 Differences between CA-MRSA and HA-MRSA 6.0 MANAGEMENT 6.1 Diagnostic evaluation 6.1.1 When to suspect CA-MRSA 6.1.2 When to obtain cultures 6.2 Treatment 6.2.1 Minor SSTIs (folliculitis, furuncles and small abscesses without cellulitis) 6.2.2 Empirical therapy of non-lifethreatening infections other than minor skin infections, potentially due to CA-MRSA 6.2.3 Empirical therapy of lifethreatening infections potentially due to CA-MRSA 6.2.4 Confirmed non-life-threatening CA-MRSA infections other than minor skin infections 6.2.5 Confirmed CA-MRSA lifethreatening infections 6.2.6 Adjunctive therapy 7.0 SCREENING AND DECOLONIZATION 7.1 Screening for CA-MRSA 7.2 Decolonization 7.3 Guidelines for the use of decolonization regimens 8.0 POPULATION SURVEILLANCE 8.1 Population surveillance program for CA-MRSA 8.2 Laboratory support 9.0 PREVENTION 9.1 Prevention of transmission of CA-MRSA 9.1.1 Role of the individual 9.1.2 Role of health care practitioners 9.1.3 Role of health authorities 9.

ClinicalTrials.gov identifier NCT00149383 .

No abstract

Carbapenemases were rare at the time of this study. Dissemination of carbapenemases was due to both dominant clones and common plasmid backbones.

No abstract